Korean firms join hands for new cancer cell therapies

Daewoong Pharmaceutical and Hanall Biopharma of South Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emerging USbased biotechnology company. The Korean firms have announced their investment in Alloplex Biotherapeutics by purchasing to support a potential long-term collaboration for developing new cancer cell therapies. Daewoong Pharmaceutical and Hanall Biopharma aim to collaborate with Alloplex to develop global networks and communication with experts in this domain. This investment will allow Alloplex to advance its first-generation SUPLEXA therapeutic cell programme into the clinic by the first half of 2022. SUPLEXA Therapeutic Cells are a differentiated and non-engineered autologous therapy made from activated and reprogrammed peripheral blood mononuclear cells (PBMC) - derived from patient whole blood. SUPLEXA cells are generated rapidly and in abundance through a robust ex vivo manufacturing procedure during which they acquire the capacity to kill all tumour cells tested without affecting normal cells.